Sarissa Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Sarissa Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6M	Hold	116,533	–	–	11.04%	4
2026 Q1	$15.4M	Sell	116,533 -186,618	-62%	-$24.8M	9.74%	4
2025 Q4	$43M	Hold	303,151	–	–	19.29%	3
2025 Q3	$42.6M	Hold	303,151	–	–	23.59%	2
2025 Q2	$38.1M	Sell	303,151 -5,965	-2%	-$684K	24.68%	2
2025 Q1	$34.2M	Hold	309,116	–	–	22.1%	2
2024 Q4	$42.2M	Sell	309,116 -101,367	-25%	-$12.5M	13.07%	3
2024 Q3	$47.3M	Hold	410,483	–	–	11.76%	5
2024 Q2	$56.5M	Buy	410,483 +64,057	+18%	+$8.78M	9.54%	6
2024 Q1	$47.8M	Sell	346,426 -123,574	-26%	-$16.9M	8.36%	5
2023 Q4	$61.9M	Buy	470,000 +104,000	+28%	+$12M	9.54%	5
2023 Q3	$41.2M	Buy	366,000 +134,700	+58%	+$14.2M	5.55%	6
2023 Q2	$21.8M	Buy	+231,300	New	+$22.6M	2.17%	6

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sarissa Capital Management's NBIX Position: Q2 2026 in Review

Sarissa Capital Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 116,533 shares worth $19.6M. The position accounts for 11.04% of the portfolio, ranked #4.

Sarissa Capital Management first reported a position in NBIX in Q2 2023 and has held it in 13 quarters since. The position peaked at $61.9M in Q4 2023. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Sarissa Capital Management held 116,533 shares of Neurocrine Biosciences worth $19.6M as of Q2 2026.
Sarissa Capital Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 11.04% of Sarissa Capital Management's portfolio in Q2 2026, its #4 holding.
Sarissa Capital Management first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 13 quarters since.
Sarissa Capital Management's Neurocrine Biosciences position peaked at $61.9M in Q4 2023.
775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sarissa Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.